Ahmad Ainurofiq
Overview
Explore the profile of Ahmad Ainurofiq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ainurofiq A, Rahayu B, Murtadla F, Kuncahyo I, Windarsih A, Choiri S
Int J Pharm
. 2024 Jul;
661:124459.
PMID: 38996822
Resveratrol (RSV) has powerful antioxidant activities. However, the bioavailability is still limited due to low solubility and transport issues. Nanocrystal technology has been introduced to address these issues; however, the...
2.
Budiman A, Wardhana Y, Ainurofiq A, Nugraha Y, Qaivani R, Hakim S, et al.
Int J Nanomedicine
. 2024 Jan;
19:281-305.
PMID: 38229702
Drug-coformer systems, such as coamorphous and cocrystal, are gaining recognition as highly effective strategies for enhancing the stability, solubility, and dissolution of drugs. These systems depend on the interactions between...
3.
Ainurofiq A, Hidayat Y, Lestari E, Kumalasari M, Choiri S
Nanomaterials (Basel)
. 2022 Jan;
12(2).
PMID: 35055241
Bioflavonoids from grape seeds feature powerful antioxidant and immunostimulant activities, but they present problems related to solubility and bioavailability. Nanocrystal (NC) incorporated into a mesoporous carrier is a promising strategy...
4.
Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi S
Pharmaceutics
. 2018 Jul;
10(3).
PMID: 29986403
Low physical stability is the limitation of the widespread use of amorphous drugs. The co-amorphous drug system is a new and emerging method for preparing a stable amorphous form. Co-amorphous...
5.
Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi S
Res Pharm Sci
. 2018 Apr;
13(2):93-102.
PMID: 29606963
This study describes the formation of multicomponent crystal (MCC) of desloratadine (DES). The objective of this study was to discover the new pharmaceutical MCC of DES using several coformers. The...
6.
Ainurofiq A, Mauludin R, Mudhakir D, Umeda D, Soewandhi S, Putra O, et al.
Eur J Pharm Sci
. 2017 Sep;
111:65-72.
PMID: 28958892
We report the first multicomponent crystal of desloratadine, an important anti-histamine drug, with a pharmaceutically acceptable coformer of benzoic acid. The single crystal structure analysis revealed that this novel multicomponent...
7.
Ainurofiq A, Choiri S
Pharm Dev Technol
. 2016 Nov;
23(5):464-475.
PMID: 27875913
The purpose of this research was to develop an inclusion complex of meloxicam (MEL)/β-cyclodextrin (β-CD) incorporated into an orally disintegrating tablet (ODT), using statistical analysis to optimize the ODT formulation...
8.
Ainurofiq A, Choiri S, Azhari M, Siagian C, Suryadi B, Prihapsara F, et al.
Adv Pharm Bull
. 2016 Oct;
6(3):399-406.
PMID: 27766224
The aim of this research was to formulate and develop an orally disintegrating tablet (ODT) that incorporated a MEL/β-CD complex, using a quality by design (QbD) approach to enhance solubility...